Natco Pharma gets USFDA nod for Lanthanum Carbonate Tablets

India Infoline News Service | Mumbai | August 14, 2017 16:02 IST

Natco Pharma announced on Monday that the company has received the final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base).

Natco Pharma announced on Monday that the company has received the final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for Lanthanum Carbonate Chewable Tablets 500 mg (base), 750 mg (base), and 1000 mg (base).
 
The product, as the first generic, will be launched shortly in the USA market.
 
The Lanthanum Carbonate Chewable Tablets are generic equivalents of Shire Development LLC’s Fosrenol Chewable Tablets and are indicated to reduce serum phosphate in patients with End Stage Renal Disease (ESRD). 
 
Fosrenol Chewable Tablets has US sales of USD 122.4 million (Rs 785 crore), as per latest data provided by IMS.  Lupin and Natco had entered into an agreement on September 1, 2008 to jointly commercialise generic equivalents of Fosrenol Chewable Tablets.
 
Meanwhile, the stock ended higher by 5.48% at Rs 741 per share on BSE.
 
Stock View:
 
Natco Pharma Ltd ended at Rs 739.3, up by Rs 36.8 or 5.24% from its previous closing of Rs 702.5 on the BSE.
 
The scrip opened at Rs 710 and touched a high and low of Rs 746 and Rs 707.55 respectively. A total of 1326377(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 12245.12 crore.
 
The BSE group 'A' stock of face value Rs 2 touched a 52 week high of Rs 1080 on 09-Jun-2017 and a 52 week low of Rs 495 on 09-Nov-2016. Last one week high and low of the scrip stood at Rs 986.55 and Rs 671.25 respectively.
 
The promoters holding in the company stood at 51.16 % while Institutions and Non-Institutions held 27.06 % and 21.78 % respectively.
 
The stock traded below its 50 DMA.

***Note: This is a NSE Chart

Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.